Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tofacitinib + vedolizumab
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Combination therapy of tofacitinib and vedolizumab for inflammatory bowel disease (IBD), particularly ulcerative colitis. This dual-targeted approach combines tofacitinib, an oral JAK inhibitor that blocks inflammatory cytokine signals, with vedolizumab, a gut-selective monoclonal antibody that prevents lymphocyte migration to the intestinal tissue by blocking α4β7 integrin interaction with MAdCAM-1. The combination has shown promise in treatment-refractory IBD patients by improving inflammatory markers, reducing clinical disease activity, and decreasing steroid dependence.
- Brand names
- EntyvioXeljanz
- Other names
- vedolizumab + tofacitinib
02
Targets
JAK3 (Janus kinase 3)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on tofacitinib + vedolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tofacitinib + vedolizumab.